362 related articles for article (PubMed ID: 12124336)
21. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D.
Zhang C; Zhang J; Niu J; Zhou Z; Zhang J; Tian Z
Hum Immunol; 2008 Aug; 69(8):490-500. PubMed ID: 18619507
[TBL] [Abstract][Full Text] [Related]
22. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
Sung CK; Choi B; Wanna G; Genden EM; Woo SL; Shin EJ
Laryngoscope; 2008 Feb; 118(2):237-42. PubMed ID: 18043494
[TBL] [Abstract][Full Text] [Related]
23. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck.
Kim SH; Wong RJ; Kooby DA; Carew JF; Adusumilli PS; Patel SG; Shah JP; Fong Y
Eur J Cancer; 2005 Jan; 41(2):313-22. PubMed ID: 15661558
[TBL] [Abstract][Full Text] [Related]
24. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
[TBL] [Abstract][Full Text] [Related]
25. IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway.
Song H; Hur DY; Kim KE; Park H; Kim T; Kim CW; Bang S; Cho DH
Cell Immunol; 2006 Jul; 242(1):39-45. PubMed ID: 17070508
[TBL] [Abstract][Full Text] [Related]
26. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
[TBL] [Abstract][Full Text] [Related]
27. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
[TBL] [Abstract][Full Text] [Related]
28. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer.
Spanos WC; Nowicki P; Lee DW; Hoover A; Hostager B; Gupta A; Anderson ME; Lee JH
Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1137-46. PubMed ID: 19917928
[TBL] [Abstract][Full Text] [Related]
29. Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors.
Tai KF; Chen PJ; Chen DS; Hwang LH
J Gene Med; 2003 May; 5(5):386-98. PubMed ID: 12731087
[TBL] [Abstract][Full Text] [Related]
30. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
[TBL] [Abstract][Full Text] [Related]
31. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
[TBL] [Abstract][Full Text] [Related]
32. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma.
Kondo N; Tsukuda M; Kimura M; Fujita K; Sakakibara A; Takahashi H; Ishiguro Y; Toth G; Matsuda H
Oncol Rep; 2010 Feb; 23(2):355-63. PubMed ID: 20043095
[TBL] [Abstract][Full Text] [Related]
33. Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression.
Qin H; Valentino J; Manna S; Tripathi PK; Bhattacharya-Chatterjee M; Foon KA; O'Malley BW; Chatterjee SK
Mol Ther; 2001 Dec; 4(6):551-8. PubMed ID: 11735339
[TBL] [Abstract][Full Text] [Related]
34. Combination gene therapy for oral cancer in a murine model.
O'Malley BW; Cope KA; Chen SH; Li D; Schwarta MR; Woo SL
Cancer Res; 1996 Apr; 56(8):1737-41. PubMed ID: 8620485
[TBL] [Abstract][Full Text] [Related]
35. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners.
Radaeva S; Sun R; Jaruga B; Nguyen VT; Tian Z; Gao B
Gastroenterology; 2006 Feb; 130(2):435-52. PubMed ID: 16472598
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model.
Chen B; Timiryasova TM; Andres ML; Kajioka EH; Dutta-Roy R; Gridley DS; Fodor I
Cancer Gene Ther; 2000 Nov; 7(11):1437-47. PubMed ID: 11129286
[TBL] [Abstract][Full Text] [Related]
37. Alloantigen gene therapy for head and neck cancer: evaluation of animal models.
Gleich LL; Li YQ; Li S; Gluckman JL; Stambrook PJ
Head Neck; 2003 Apr; 25(4):274-9. PubMed ID: 12658731
[TBL] [Abstract][Full Text] [Related]
38. FasL gene therapy: a new therapeutic modality for head and neck cancer.
ElOjeimy S; McKillop JC; El-Zawahry AM; Holman DH; Liu X; Schwartz DA; Day TA; Dong JY; Norris JS
Cancer Gene Ther; 2006 Aug; 13(8):739-45. PubMed ID: 16543918
[TBL] [Abstract][Full Text] [Related]
39. The effect of silencing NKG2D through RNA interference on receptor functions in interleukin-2-activated human natural killer cells.
Baeriswyl V; Wodnar-Filipowicz A; Kalberer CP
Haematologica; 2006 Nov; 91(11):1538-41. PubMed ID: 17043026
[TBL] [Abstract][Full Text] [Related]
40. Combined treatment of cisplatin and overexpression of caspase-activated deoxyribonuclease (CAD) promotes apoptosis in vitro and in vivo.
Kimura Y; Sugimoto C; Matsukawa S; Sunaga H; Igawa H; Yamamoto H; Ito T; Saito H; Fujieda S
Oral Oncol; 2004 Apr; 40(4):390-9. PubMed ID: 14969818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]